Elon Musk’s Neuralink company has announced that it is now accepting participants for its first in-human study, called PRIME (Precise Robotically Implanted Brain-Computer Interface). This study aims to assess the safety of Neuralink’s brain-computer interface (BCI) implant, as well as the functionality of the BCI in enabling individuals with paralysis to control external devices using their thoughts.
The PRIME study is specifically seeking individuals with quadriplegia caused by cervical spinal cord injury or amyotrophic lateral sclerosis (ALS). This focus on paralysis is in contrast to Musk’s previous claims that the technology would have transhumanistic applications, such as learning skills from an SD card or controlling household electronics with the mind.
However, Neuralink does have plans to develop BCIs as a means of bridging the gap between the human mind and machines. BCIs convert the electrical signals of the brain into digital signals that can be understood by machines. The N1 system developed by Neuralink utilizes a high-fidelity Utah Array of probes, which must be implanted via robotic keyhole surgery performed by Neuralink’s R1 robot surgeon. These probes are fitted onto the patient’s motor cortex and record and transmit electrical impulses to an associated app, which interprets them into actionable commands for a computer.
The initial goal of Neuralink’s BCI is to enable people to control a computer cursor or keyboard using their thoughts alone. This would be a significant advancement for individuals with paralysis, as it would provide them with a new means of communication and interaction with technology.
Neuralink has been developing the N1 system since 2017, making it one of the pioneers in the commercial BCI industry. However, the company faced setbacks last year when it was accused of causing harm and death to animal test subjects. This led to investigations on animal cruelty charges and the FDA denying Neuralink’s request to fast-track human trials. The PRIME study is now being conducted under an investigational device exemption (IDE) granted by the FDA in May of this year.
By opening enrollment for the PRIME study, Neuralink is taking a significant step towards testing the safety and functionality of its BCI technology in humans. The study will not only provide valuable data on the use of BCIs for individuals with paralysis but could also pave the way for future advancements in brain-machine interfaces.
While Neuralink aims to empower individuals with paralysis, its ultimate vision for BCIs extends beyond medical applications. Musk has previously discussed the potential for BCIs to enhance human capabilities, allowing people to learn new skills or control machines with their minds. These speculative applications are still a long way off, but by starting with the PRIME study, Neuralink is laying the groundwork for further advancements in the field.
In conclusion, Neuralink’s announcement of open enrollment for its first in-human study, PRIME, marks a milestone in the development of brain-computer interface technology. The study aims to assess the safety and functionality of Neuralink’s BCI implant, with a focus on enabling individuals with paralysis to control external devices using their thoughts. While the initial goal is to control a computer cursor or keyboard, Neuralink envisions broader applications for BCIs in the future. By participating in the PRIME study, individuals with quadriplegia have the opportunity to contribute to the advancement of BCIs and potentially improve their quality of life.
